Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial

C. Moreno, R. Greil, F. Demirkan, A. Tedeschi, B. Anz, L. Larratt, M. Simkovic, J. Novak, V. Strugov, D. Gill, JG. Gribben, K. Kwei, S. Dai, E. Hsu, JP. Dean, IW. Flinn

. 2022 ; 107 (9) : 2108-2120. [pub] 20220901

Jazyk angličtina Země Itálie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024582

iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Eligible patients were aged ≥65 years, or <65 years with coexisting conditions. Patients received oral ibrutinib 420 mg once daily until disease progression or unacceptable toxicity or six cycles of oral chlorambucil, each in combination with six cycles of intravenous obinutuzumab. After a median follow-up of 45 months (range, 0.2-52), median progression-free survival continued to be significantly longer in the ibrutinib plus obinutuzumab arm than in the chlorambucil plus obinutuzumab arm (median not reached versus 22 months; hazard ratio=0.25; 95% confidence interval: 0.16-0.39; P<0.0001). The best overall rate of undetectable minimal residual disease (<0.01% by flow cytometry) remained higher with ibrutinib plus obinutuzumab (38%) than with chlorambucil plus obinutuzumab (25%). With a median treatment duration of 42 months, 13 months longer than the primary analysis, no new safety signals were identified for ibrutinib. As is typical for ibrutinib-based regimens, common grade ≥3 adverse events were most prevalent in the first 6 months of ibrutinib plus obinutuzumab treatment and generally decreased over time, except for hypertension. In this final analysis with up to 52 months of follow-up (median 45 months), ibrutinib plus obinutuzumab showed sustained clinical benefit, in terms of progression- free survival, in first-line treatment of chronic lymphocytic leukemia, including in patients with high-risk features. ClinicalTrials.gov identifier: NCT02264574.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024582
003      
CZ-PrNML
005      
20240418101834.0
007      
ta
008      
221017s2022 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2021.279012 $2 doi
035    __
$a (PubMed)35021599
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Moreno, Carol $u Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain. cmorenoa@santpau.cat
245    10
$a First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial / $c C. Moreno, R. Greil, F. Demirkan, A. Tedeschi, B. Anz, L. Larratt, M. Simkovic, J. Novak, V. Strugov, D. Gill, JG. Gribben, K. Kwei, S. Dai, E. Hsu, JP. Dean, IW. Flinn
520    9_
$a iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Eligible patients were aged ≥65 years, or <65 years with coexisting conditions. Patients received oral ibrutinib 420 mg once daily until disease progression or unacceptable toxicity or six cycles of oral chlorambucil, each in combination with six cycles of intravenous obinutuzumab. After a median follow-up of 45 months (range, 0.2-52), median progression-free survival continued to be significantly longer in the ibrutinib plus obinutuzumab arm than in the chlorambucil plus obinutuzumab arm (median not reached versus 22 months; hazard ratio=0.25; 95% confidence interval: 0.16-0.39; P<0.0001). The best overall rate of undetectable minimal residual disease (<0.01% by flow cytometry) remained higher with ibrutinib plus obinutuzumab (38%) than with chlorambucil plus obinutuzumab (25%). With a median treatment duration of 42 months, 13 months longer than the primary analysis, no new safety signals were identified for ibrutinib. As is typical for ibrutinib-based regimens, common grade ≥3 adverse events were most prevalent in the first 6 months of ibrutinib plus obinutuzumab treatment and generally decreased over time, except for hypertension. In this final analysis with up to 52 months of follow-up (median 45 months), ibrutinib plus obinutuzumab showed sustained clinical benefit, in terms of progression- free survival, in first-line treatment of chronic lymphocytic leukemia, including in patients with high-risk features. ClinicalTrials.gov identifier: NCT02264574.
650    _2
$a adenin $x analogy a deriváty $7 D000225
650    _2
$a humanizované monoklonální protilátky $7 D061067
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $7 D000971
650    12
$a chlorambucil $7 D002699
650    _2
$a lidé $7 D006801
650    12
$a chronická lymfatická leukemie $x diagnóza $x farmakoterapie $7 D015451
650    _2
$a piperidiny $7 D010880
650    _2
$a pyrazoly $x škodlivé účinky $7 D011720
650    _2
$a pyrimidiny $7 D011743
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Greil, Richard $u 3rd Medical Department, Paracelsus Medical University, Salzburg Cancer Research Institute-CCCIT, Salzburg, Austria
700    1_
$a Demirkan, Fatih, $d 1965- $u Dokuz Eylul University, Division of Hematology, Izmir, Turkey $7 xx0316387
700    1_
$a Tedeschi, Alessandra $u Niguarda Ca' Granda Hospital, Milan, Italy
700    1_
$a Anz, Bertrand $u Tennessee Oncology, Chattanooga, TN, USA
700    1_
$a Larratt, Loree $u University of Alberta Hospital, Edmonton, Alberta, Canada
700    1_
$a Simkovic, Martin $u Department of Internal Medicine, Haematology, University Hospital and Medical School Hradec, Králové, Czech Republic
700    1_
$a Novak, Jan $u University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Strugov, Vladimir $u Almazov National Medical Research Centre, St. Petersburg, Russia
700    1_
$a Gill, Devinder $u Princess Alexandra Hospital, Brisbane, Queensland, Australia
700    1_
$a Gribben, John G $u Barts Cancer Institute, London, United Kingdom
700    1_
$a Kwei, Kevin $u Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA
700    1_
$a Dai, Sandra $u Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA
700    1_
$a Hsu, Emily $u Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA
700    1_
$a Dean, James P $u Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA
700    1_
$a Flinn, Ian W $u Sarah Cannon Research Institute, Nashville, TN, USA
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 107, č. 9 (2022), s. 2108-2120
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35021599 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20240418101828 $b ABA008
999    __
$a ok $b bmc $g 1854353 $s 1175872
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 107 $c 9 $d 2108-2120 $e 20220901 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
LZP    __
$a Pubmed-20221017
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace